OTCM
RIBT
Market cap0kUSD
Oct 06, Last price
0.00USD
1Q
-99.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
RiceBran Technologies
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
RiceBran Technologies, along with its associated companies, functions as a specialized purveyor of ingredients. Its core business revolves around the development, processing, and distribution of premium, wholesome, and nutrient-rich products, sourced primarily from rice and other select small grains. The company adeptly transforms raw rice bran into stabilized rice bran (SRB) and subsequently into a suite of high-value derivative products. These include RiBalance, a comprehensive nutritional offering created by refining SRB; RiSolubles, a carbohydrate and lipid-dense fraction extracted from RiBalance; RiFiber, an insoluble protein and fiber-rich byproduct of RiBalance; and the ProRyza range, encompassing various protein or protein/fiber formulations. These SRB and derivative products are highly nutritious and advantageous, packed with a beneficial blend of oils, proteins, carbohydrates, essential vitamins, minerals, fibers, and antioxidants, significantly boosting the nutritional profile of end-consumer goods. In addition to human food applications, the company's SRB products are also supplied as essential feed components within the animal nutrition sector. RiceBran Technologies serves a diverse clientele, including manufacturers in both the food and animal nutrition industries, as well as wholesalers and retailers, operating across both domestic (United States) and international markets. Established in 2000 and based in Tomball, Texas, the enterprise initially operated as NutraCea before rebranding as RiceBran Technologies in October 2012.
Key people
Eric Tompkins
Executive Chairman of the Board · since 2023
William Keneally
Chief Financial Officer, Company Secretary, Director · since 2024
James Flynn
Independent Director · since 2024
Legal address
C/O JEFF PIETSCH
475 SANSOME STREET
SUITE 510
SAN FRANCISCO, CA 94111
US
475 SANSOME STREET
SUITE 510
SAN FRANCISCO, CA 94111
US
Headquarters
25420 KUYKENDAHL RD.
SUITE B300
TOMBALL, TX 77375
US
SUITE B300
TOMBALL, TX 77375
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||